Associate Professor Chris Layton
Associate Professor

Chris Layton

Email: 
Phone: 
+61 7 3443 7000

Background

Professor Layton is a national leader in innovative ophthalmology, with expertise in macular disease, lens surgery and minimally invasive glaucoma interventions. He completed ophthalmology training in Queensland, Oxford and London, subspecialty training in retinal disease at the Royal Brisbane Hospital and holds a PhD in diabetic retinopathy from Oxford University. Professor Layton is a Rhodes Scholar and founding director of the LVF Ophthalmology Research Centre in Brisbane, Australia. He is also CEO of Ocugene, a Queensland based biotech start-up which is commercialising his gene therapy technology targeting macular degeneration, uveitis and choroidal melanoma. Professor Layton is the listed inventor of multiple ophthalmic patent applications currently under review in the USA, the EU, Japan, Israel, Australia and Singapore. He has published extensively in the international literature and his work has been recognised by awards from international eye research organisations.

Availability

Associate Professor Chris Layton is:
Available for supervision

Fields of research

Biomedical and Clinical Sciences Ophthalmology Ophthalmology and optometry

Qualifications

  • Bachelor, Queensland University of Technology
  • Bachelor of Medicine Surgery, The University of Queensland
  • Doctor of Philosophy, University of Oxford
  • Royal Australian and New Zealand College of Ophthalmologists, Royal Australian and New Zealand College of Ophthalmologists

Research interests

  • Ophthalmology

  • Gene therapy

  • Intraocular drug delivery and targeting

  • Medical retina disease

  • Retinal angiogenesis

  • Diabetic Retinopathy

Research impacts

The LVF Ophthalmology Research Centre is a prominent ophthalmologist led research unit in Queensland. The unit’s research focus is on optimising next generation targeted therapeutics for the intravitreal treatment of currently blinding or fatal medical retinal conditions. Our world class infrastructure includes modern, extensively equipped PC2 laboratories and access to on site flow cytometry; confocal, multiphoton and 3D scanning super resolution microscopy; microPET imaging and mass spectrometry. The unit has developed a complete bench to bedside development pipeline through our clinical research infrastructure, from high technology discovery work of targeted therapeutics in cell culture systems to unit sponsored clinical trials. Academic training is a specialty of the unit and forms the ideal foundation for a career as a visual scientist, neuroscientist or academic ophthalmologist. Alternatively, experiences in the unit can be tailored to impart a high level of ophthalmic knowledge prior to undertaking the RANZCO ophthalmology training program or equivalency examinations. Supervision is supportive and directed towards the career goals of the Centre's members, not the advancement of the Centre itself.

Search Professor Chris Layton’s works on UQ eSpace

52 works between 2002 and 2024
All (52) Journal Article (35) Conference Publication (16) Other Outputs (1)

41 - 52 of 52 works

2016

Journal Article

Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review

Goh, Amanda Y. L. and Layton, Christopher J. (2016). Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review. Clinical and Experimental Ophthalmology, 44 (6), 509-519. doi: 10.1111/ceo.12688

Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review

2015

Journal Article

Diabetic levels of glucose increase cellular reducing equivalents but reduce survival in three models of 661W photoreceptor-like cell injury

Layton, Christopher J. (2015). Diabetic levels of glucose increase cellular reducing equivalents but reduce survival in three models of 661W photoreceptor-like cell injury. BMC Ophthalmology, 15 (174) 174, 174. doi: 10.1186/s12886-015-0164-2

Diabetic levels of glucose increase cellular reducing equivalents but reduce survival in three models of 661W photoreceptor-like cell injury

2015

Conference Publication

The effect of glucose and insulin on the susceptibility of cultured photoreceptor-like cells to hypoxia

Layton, C. J. and de Moraes, G. (2015). The effect of glucose and insulin on the susceptibility of cultured photoreceptor-like cells to hypoxia. European Association for Vision and Eye Research Conference, Nice, France, 7-10 Oct. 2015. Hoboken, NJ, United States: Wiley-Blackwell. doi: 10.1111/j.1755-3768.2015.0711

The effect of glucose and insulin on the susceptibility of cultured photoreceptor-like cells to hypoxia

2007

Journal Article

Oscillatory potentials and the b-Wave: partial masking and interdependence in dark adaptation and diabetes in the rat

Layton, C. J., Safa, R. and Osborne, N. N. (2007). Oscillatory potentials and the b-Wave: partial masking and interdependence in dark adaptation and diabetes in the rat. Graefe's Archive for Clinical and Experimental Ophthalmology, 245 (9), 1335-1345. doi: 10.1007/s00417-006-0506-0

Oscillatory potentials and the b-Wave: partial masking and interdependence in dark adaptation and diabetes in the rat

2006

Journal Article

The effect of insulin and glucose levels on retinal glial cell activation and pigment epithelium-derived fibroblast growth factor-2

Layton, C. J., Becker, S. and Osborne, N. N. (2006). The effect of insulin and glucose levels on retinal glial cell activation and pigment epithelium-derived fibroblast growth factor-2. Molecular Vision, 12, 46-54.

The effect of insulin and glucose levels on retinal glial cell activation and pigment epithelium-derived fibroblast growth factor-2

2006

Journal Article

The effect of insulin and glucose levels on retinal glial cell activation and pigment epithelium-derived fibroblast growth factor-2

Layton, CJ, Becker, S and Osborne, NN (2006). The effect of insulin and glucose levels on retinal glial cell activation and pigment epithelium-derived fibroblast growth factor-2. Molecular Vision, 12 (5), 43-54.

The effect of insulin and glucose levels on retinal glial cell activation and pigment epithelium-derived fibroblast growth factor-2

2005

Journal Article

Survey of eye practitioners' attitudes towards diagnostic tests and therapies for dry eye disease

Turner, Angus W., Layton, Christopher J. and Bron, Anthony J. (2005). Survey of eye practitioners' attitudes towards diagnostic tests and therapies for dry eye disease. Clinical and Experimental Ophthalmology, 33 (4), 351-355. doi: 10.1111/j.1442-9071.2005.01026.x

Survey of eye practitioners' attitudes towards diagnostic tests and therapies for dry eye disease

2005

Journal Article

Neuronal death in primary retinal cultures is related to nitric oxide production, and is inhibited by erythropoietin in a glucose-sensitive manner

Layton, C. J., Chidlow, G., Wood, J. P. M. and Osborne, N. N. (2005). Neuronal death in primary retinal cultures is related to nitric oxide production, and is inhibited by erythropoietin in a glucose-sensitive manner. Journal of Neurochemistry, 92 (3), 487-493. doi: 10.1111/j.1471-4159.2004.02876.x

Neuronal death in primary retinal cultures is related to nitric oxide production, and is inhibited by erythropoietin in a glucose-sensitive manner

2004

Conference Publication

Erythropoietin assists neuronal survival and reduces nitric oxide production in retinal cultures at low but not moderate glucose concentrations.

Layton, CJ, Wood, JPM, Turner, A and Osborne, NN (2004). Erythropoietin assists neuronal survival and reduces nitric oxide production in retinal cultures at low but not moderate glucose concentrations.. Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology, Ft Lauderdale Fl, Apr 24-29, 2004. ROCKVILLE: ASSOC RESEARCH VISION OPHTHALMOLOGY INC.

Erythropoietin assists neuronal survival and reduces nitric oxide production in retinal cultures at low but not moderate glucose concentrations.

2004

Journal Article

Optic nerve and neuroprotection strategies

Osborne, N. N., Chidlow, G., Layton, C. J., Wood, J. P. M., Casson, R. J. and Melena, J. (2004). Optic nerve and neuroprotection strategies. Eye, 18 (11), 1075-1084. doi: 10.1038/sj.eye.6701588

Optic nerve and neuroprotection strategies

2003

Conference Publication

Localisation of monocarboxylate transporter subtypes 1-4 in the rat eye

Osborne, NN, Layton, CJ, Wood, JPM, Graham, M and Chidlow, G (2003). Localisation of monocarboxylate transporter subtypes 1-4 in the rat eye. Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology, Ft Lauderdale Florida, May 04, 2003. ROCKVILLE: ASSOC RESEARCH VISION OPHTHALMOLOGY INC.

Localisation of monocarboxylate transporter subtypes 1-4 in the rat eye

2002

Journal Article

Clinical aspects of conjunctival melanoma

Layton, Christopher Layton and Glasson, William (2002). Clinical aspects of conjunctival melanoma. Clinical and Experimental Ophthalmology, 30 (2), 72-79. doi: 10.1046/j.1442-6404.2002.00490.x

Clinical aspects of conjunctival melanoma

Past funding

  • 2016 - 2019
    Aspects of diabetic retinal neuropathy and diabetic retinopathy
    Layton Vision Foundation Limited
    Open grant
  • 2016 - 2020
    Aspects of posterior segment therapeutic targeting in retinal disease
    Gallipoli Medical Research Foundation
    Open grant
  • 2014 - 2017
    Diabetic Retinal Neuropathy in the Outer Retina
    Gallipoli Medical Research Foundation
    Open grant

Availability

Associate Professor Chris Layton is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • 1. Penetrative intraviteal anti-angiogenic gene therapy approaches for sub-RPE choroidal neovascularisation in exudative macular degeneration

  • 2. Intravitreal modulated immunotherapy for severe choroidal inflammation

  • 3. Penetrative intravitreal cancer gene therapy for the treatment of uveal melanoma

  • 4. EPO as a neuroprotective agent in human diabetic retinal neuropathy associated with nephropathy

    Requires AHPRA registration and a clinical degree

Supervision history

Current supervision

  • Doctor Philosophy

    Penetrative intraviteal gene therapy approaches to macular degeneration

    Principal Advisor

Completed supervision

Enquiries

For media enquiries about Associate Professor Chris Layton's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au